Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Her-2/neu test predicts drug response

This article was originally published in The Gray Sheet

Executive Summary

Metastatic breast cancer patients whose serum Her-2/neu levels decrease by less than 20% in response to trastuzumab therapy are unlikely to benefit from the anti-cancer drug, according to a Bayer Diagnostics study. The 307-patient study found that women with a less than 20% reduction in Her-2/neu levels had a shorter duration of response and a decreased overall survival rate. Bayer suggests that the Her-2/neu test could be used as an early predictor of a patient's response to trastuzumab therapy, allowing doctors to optimize treatment regimens...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel